183 related articles for article (PubMed ID: 37449538)
1. Clinical manifestations and susceptibility of Scedosporium/Lomentospora infections at a tertiary medical centre in Taiwan from 2014 to 2021: A retrospective cohort study.
Lao CK; Ou JH; Fan YC; Wu TS; Sun PL
Mycoses; 2023 Oct; 66(10):923-935. PubMed ID: 37449538
[TBL] [Abstract][Full Text] [Related]
2. Scedosporiosis/lomentosporiosis observational study (SOS): Clinical significance of Scedosporium species identification.
Bronnimann D; Garcia-Hermoso D; Dromer F; Lanternier F; ;
Med Mycol; 2021 May; 59(5):486-497. PubMed ID: 33037432
[TBL] [Abstract][Full Text] [Related]
3. Pandemic Response Box® library as a source of antifungal drugs against Scedosporium and Lomentospora species.
Rollin-Pinheiro R; Xisto MIDDS; de Castro-Almeida Y; Rochetti VP; Borba-Santos LP; Fontes YDS; Ferreira-Pereira A; Rozental S; Barreto-Bergter E
PLoS One; 2023; 18(2):e0280964. PubMed ID: 36735743
[TBL] [Abstract][Full Text] [Related]
4.
Seyedmousavi S; Chang YC; Youn JH; Law D; Birch M; Rex JH; Kwon-Chung KJ
Antimicrob Agents Chemother; 2021 Sep; 65(10):e0043421. PubMed ID: 34252298
[TBL] [Abstract][Full Text] [Related]
5. Decoding the antifungal resistance mechanisms in biofilms of emerging, ubiquitous and multidrug-resistant species belonging to the Scedosporium/Lomentospora genera.
Mello TP; Oliveira SSC; Branquinha MH; Santos ALS
Med Mycol; 2022 Jun; 60(6):. PubMed ID: 35641191
[TBL] [Abstract][Full Text] [Related]
6. Invasive bone and joint infections from the French Scedosporiosis/lomentosporiosis Observational Study (SOS) cohort: no mortality with long-term antifungal treatment and surgery.
Blez D; Bronnimann D; Rammaert B; Zeller V; Delhaes L; Hustache L; Grenouillet F; Traversier N; Bonhomme J; Chouaki T; Perpoint T; Persat F; Bougnoux ME; Bayle S; Quaesaet L; Nevez G; Boutoille D; Morio F; Pougnet L; Queyrel-Moranne V; Heym BE; Guillemain R; Dannaoui É; Roux A; Garcia-Hermoso D; Lanternier F
Med Mycol; 2023 Mar; 61(3):. PubMed ID: 36813259
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility of Pseudallescheria boydii and Scedosporium apiospermum to new antifungal agents.
Zeng J; Kamei K; Zheng Y; Nishimura K
Nihon Ishinkin Gakkai Zasshi; 2004; 45(2):101-4. PubMed ID: 15118667
[TBL] [Abstract][Full Text] [Related]
8. Invasive Scedosporium and Lomentosora infections in the era of antifungal prophylaxis: A 20-year experience from a single centre in Spain.
Álvarez-Uría A; Guinea JV; Escribano P; Gómez-Castellá J; Valerio M; Galar A; Vena A; Bouza E; Muñoz P
Mycoses; 2020 Nov; 63(11):1195-1202. PubMed ID: 32749009
[TBL] [Abstract][Full Text] [Related]
9. Scedosporium aurantiacum: First isolation in Argentina from a previously healthy patient after traumatic inoculation.
Carnovale S; Epelbaum C; Abrantes R; Córdoba S; Cabrera C; Caracciolo B
Rev Argent Microbiol; 2022; 54(4):318-321. PubMed ID: 35643584
[TBL] [Abstract][Full Text] [Related]
10. Dihydroorotate dehydrogenase inhibitor F901318 has potent in vitro activity against Scedosporium species and Lomentospora prolificans.
Wiederhold NP; Law D; Birch M
J Antimicrob Chemother; 2017 Jul; 72(7):1977-1980. PubMed ID: 28333310
[TBL] [Abstract][Full Text] [Related]
11. Genotypic diversity and antifungal susceptibility of Scedosporium species from clinical settings in China.
Chen M; Zhu X; Cong Y; Chen H; Hou Q; Hong N; Chen X; Lei W; Cai J; Lu X; Shuai L; Li X; Deng S; Xu J; Liao W; Pan W; Xu H; de Hoog S
Mycoses; 2022 Dec; 65(12):1159-1169. PubMed ID: 35899426
[TBL] [Abstract][Full Text] [Related]
12. Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species.
Lackner M; de Hoog GS; Verweij PE; Najafzadeh MJ; Curfs-Breuker I; Klaassen CH; Meis JF
Antimicrob Agents Chemother; 2012 May; 56(5):2635-42. PubMed ID: 22290955
[TBL] [Abstract][Full Text] [Related]
13. A systematic review and disability-adjusted life years of Scedosporium/Lomentospora infection in patients after near-drowning.
Kermani F; Yazdani Charati J; Roohi B; Moslemi A; Bandeghani A; Faeli L; Shokohi T; Roilides E
Mycoses; 2024 Feb; 67(2):e13703. PubMed ID: 38345265
[TBL] [Abstract][Full Text] [Related]
14.
Georgacopoulos O; Nunnally N; Law D; Birch M; Berkow EL; Lockhart SR
Microbiol Spectr; 2023 Feb; 11(1):e0278922. PubMed ID: 36629417
[No Abstract] [Full Text] [Related]
15.
Furnica DT; Dittmer S; Scharmann U; Meis JF; Steinmann J; Rath PM; Kirchhoff L
Microbiol Spectr; 2023 Jun; 11(3):e0513022. PubMed ID: 37017567
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of olorofim against clinical isolates of Scedosporium species and Lomentospora prolificans using EUCAST and CLSI methodologies.
Rivero-Menendez O; Cuenca-Estrella M; Alastruey-Izquierdo A
J Antimicrob Chemother; 2020 Dec; 75(12):3582-3585. PubMed ID: 32856079
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology, clinical manifestations, and outcomes of Scedosporium infections among solid organ transplant recipients.
Johnson LS; Shields RK; Clancy CJ
Transpl Infect Dis; 2014 Aug; 16(4):578-87. PubMed ID: 24962102
[TBL] [Abstract][Full Text] [Related]
18. Assessing micafungin/triazole combinations for the treatment of invasive scedosporiosis due to Scedosporium apiospermum and Scedosporium boydii.
Lackner M; Fernández-Silva F; Guarro J; Lass-Flörl C
J Antimicrob Chemother; 2014 Nov; 69(11):3027-32. PubMed ID: 24986494
[TBL] [Abstract][Full Text] [Related]
19. Effects of Photodynamic Therapy on the Growth and Antifungal Susceptibility of Scedosporium and Lomentospora spp.
Lu Q; Sun Y; Tian D; Xiang S; Gao L
Mycopathologia; 2017 Dec; 182(11-12):1037-1043. PubMed ID: 28836110
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of the novel antifungal compound F901318 against Australian Scedosporium and Lomentospora fungi.
Biswas C; Law D; Birch M; Halliday C; Sorrell TC; Rex J; Slavin M; Chen SC
Med Mycol; 2018 Nov; 56(8):1050-1054. PubMed ID: 29370408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
